Mental Health and Suicidal Thoughts in People with Glioblastoma
Studies questionnaires on depression, anxiety and suicidal thoughts in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Mental Health and Suicidality in Glioblastoma Patients in Germany
Key facts
- Where
- Berlin, Bochum, Essen, Hamburg, Heidelberg, and Münster, GermanySee the 6 sites
Where in Germany
- ChariteBerlin, GermanyTaking people
- University Hospital Knappschaftskrankenhaus BochumBochum, GermanyNot yet recruiting
- University Hospital EssenEssen, GermanyTaking people
- University hospital Hamburg EppendorfHamburg, GermanyTaking people
- University Hospital HeidelbergHeidelberg, GermanyTaking people
- University hospital MuensterMünster, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Essen
- Trial code
- NCT07409584
- Record updated
- 27 August 2026
- Original description
The aim of the study is to use standardized questionnaires to systematically record influencing factors or predictors for suicidal behavior in glioblastoma patients, particularly with regard to existing depression and anxiety symptoms.Read full original descriptionShow less
Mental Health and Suicidality in Glioblastoma Patients in Germany - a Multicenter Observational Study (SHINE-GLIO Study)
The aim of the study is to use standardized questionnaires to systematically record influencing factors or predictors for suicidal behavior in glioblastoma patients, particularly with regard to existing depression and anxiety symptoms.
Inclusion: Newly diagnosed glioblastoma, IDH wild-type (CNS WHO classification of 2021) after finishing radiotherapy (before first recurrence); Age ≥ 18 years.
Exclusion: History of other malignant tumors; Known tumor predisposition syndrome (e.g., Li-Fraumeni syndrome, Cowden syndrome, etc.); Participants with clinically significant aphasia or language barrier as assessed by the investigator; Recurrent glioblastoma.